'We Need Medicines' Rare Disease Patients Cry As China Lockdowns Disrupt Supplies
Remote Tools Of Little Help
As cases continues soaring and infections spreading in China, pharma supply chain crunch starts biting and many wonder how long the country can sustain its strictest Zero Covid policy and start living with the virus like the rest of the world.
You may also be interested in...
The latest mega deals aimed at bringing Chinese innovation to the US have rekindled go-global hopes for a sector badly needing some cheer. But some investors say out-licensing may be the best route and that Chinese biotech must scale back its do-all mentality and focus on what it does best amid a new reality.
The hard going could get even tougher as a funding crunch continues for China’s biotech sector, which is being hit by a paradox that could see more pain ahead, leading investors to take the pulse of the sector as the Year of the Rabbit starts.
From orphan to cancer drugs, more products have had their prices cut in the latest round of reimbursement negotiations in China. Although the 60% average across 100 medicines was considered mild given it didn’t go beyond the previous year, it was still chilling and is prompting more firms, both multinational and domestic, to walk away from the process.